Since 2000, when Promise was introduced, the Austrian Stem Cell Transplantation Registry (ASCTR) has been using the EBMT database as national registry database. We have been collecting MED-A-Data of all HSCT performed in Austria since 1978 from all registered transplant centers, including by now 3832 allogeneic and 5897 autologous transplants. Main disease categories in the allogeneic setting are AML (n = 1233) and Precursor Lymphoid Neoplasms (n = 665), in the autologous setting NHL (n = 1384) and Multiple Myeloma (n = 2190). The ratio adult versus paediatric transplants is 8269 versus 1460. In addition, we use the EBMT data base for collecting data on family donor outcome. Furthermore, data on stem cell harvests has been collected locally since 2005. The ASCTR is obliged to report data on patient and disease demographics quarterly to the Austrian health authorities. For this purpose we keep these data in a local database that is linked to the EBMT database. Central data entry through the ASCTR includes immediate queries to reporting centers if data are missing or incorrect. Additional data quality checks are done on an annual basis when the data is analysed for the annual report on HSCT in Austria. This procedure has proved feasible and useful over the past years. So far, only two Austrian centers, both pediatric, have entered their data directly using Promise. All other Med-A data sets have been sent as paper version by the centers and have been entered centrally via the ASCTR. From 2017 onwards the Austrian centers are obliged to switch to online data entry, in accordance with the requirements of the EBMT to go paper free in 2017. We plan to do the necessary training courses for data entry within the first two to four months of the coming year, allowing a smooth transition. In order to encourage members of the Austrian Group for Stem Cell Transplantation (AGSCT) to use ASCTR data as starting point for new studies and other research projects, the ASCTR will focus on data quality issues including patient and disease demographics such as pretransplant comorbidities, disease stage, cytogenetic and molecular markers and follow-up reports to allow transplant outcome analyses that will be included in the annual report of the Ministry of Health in the near future. Each contributing center should have easy access to frequently needed analyses of their own data to be used for quality control of local transplant practices and for preparation of JACIE audits. Furthermore, donor follow-up data will be linked to a national database located at the transplant agency of the Ministry of Health to allow analyses on safety issues of hematopoietic stem cell donation and long-term side-effects.
As an alternative to the use of EBMT database downloads for local analyses the establishment of a separate database combining all Austrian transplant and harvest centers has been discussed within the AGSCT. Besides being more costly, this strategy would result in decreased use of the EBMT database and centers, providing a minimum of data to EBMT since the vast majority of data collected would be stored in another database separate from EBMT. Hopefully, within due time a decision among our centers regarding database use will be made to foster further research projects and outcome analyses of both transplant recipients as well as donors. Disclosure of conflict of interest: None. Patient and outcome data collection is an integral component of participation in national and international SCT registries. Data reporting and research projects require prospective consent before collation and transmission. We performed an audit of consent for research data collection and transmission at our centre and identified factors associated with lack of consent status prior to SCT. Patients and Method: A retrospective cohort study identified 1,117 patients receiving 1,283 transplants between August 1987 and June 2016. Minimum follow-up was 100 days. 43.4% were consented and 56.6% were non-consented (i.e., deceased before consent [n = 403], explicitly refused consent [n = 2], alive and on active follow-up but did not respond [n = 114] , and lost to follow [n = 113] ). Factors contributing to consent status were identified and impact on survival outcomes was assessed. Results: Non-consented vs consented patients were significantly more likely to suffer post-transplant mortality (63.9% vs 27.2, Po0.001), be lost to follow-up (17.9% vs 14%, Po0.001), be from outside major city (29.3% vs 22%, Po0.001), be o61 y/o at first transplant (70.4% vs 60.4%, Po0.001), receive autologous cells as first transplant (74.7% vs 65.8%, Po0.001), to suffer more relapse (41% vs 34.6%, P = 0.003) and die within 100days post-transplant (14.7% vs 1.9%, Po0.001). Median time to relapse is 293 days vs 364 days (P = 0.039). Using logistic regression analysis, 71.1% (Po0.001) of variance in consent rates could be predicted by the significant variables with survival status and day 100 mortality being the most highly correlated variables predicting lack of consent. Overall survival (OS) rates (Po0.001) and disease-free survival (DFS) rates (Po0.001) were consistently higher for consented vs nonconsented patients at all time points assessed post-SCT. (Figures  1, 2 ) Conclusion: High rates of non-consent in data collection and transmission may impact on the utility of national and international SCT databases. In this single-centre retrospective audit, high rates of non-consent were associated with younger age at transplant, regional residence and poorer outcome. This study highlights a selected cohort of patients who may benefit from additional strategies for obtaining consent for data collection and transmission prior to SCT. Disclosure of conflict of interest: None. The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) has been collecting details of haemopoietic stem cell transplants in Australia and New Zealand since 1992. The registry is managed by the Bone Marrow Transplant Society of Australia and New Zealand, and whilst registry reporting is not mandatory, it is believed the ABMTRR has close to full enumeration of transplant activity in these two countries. However, collection of follow up data varies from centre to centre and can be an administrative burden for hospital respondents. The online database system developed in 2013 has helped to streamline the data submission process. Data quality monitoring, previously performed for the whole database, is now performed for each centre and reported back to them for comparison with the total database each quarter. Database reports are available to help address these data quality measures, as well as requirements for specific analyses. Measures of data quality that will impact most on analysis of outcomes for benchmarking purposes have been defined. These include the percentage of patients with one year follow up data available and the percentage of patients with survival data in the past two years (or death recorded), which we use as an indicator of data currency. The inaccuracies were instances of responses being overstated (n = 10) or understated (n = 7). Post review: 7 were upstaged: PR-VGPR = 3, VGPR-sCR = 1 and CR-sCR = 3. 10 were down staged: CR-VGPR=7 (6 due a lack of a negative immunofixation test/ bone marrow), VGPR-PR = 1, and PR-progression = 2. Inaccuracies in HCT-CI score (n = 7, 9.6%) were simply down to clinicians not thoroughly checking pre-BMT tests against the HCT-CI criteria. In Durie-Salmon staging inaccuracies (n = 14, 15.1%), 6 were a result of staging being applied when not technically possible i.e. not all diagnostic tests were actually performed. Six were stated as stage I/II, but post review were in fact stage III. Two involved differences between the A/B component (serum creatinine) of the staging. Most inaccuracies were attributed to clinicians not having access to the primary source data at time of transplant. Although requested at referral, compliance by referrers is generally poor. Source data is obtained by the Data Manager. 
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Taiwan is an endemic area for Hepatitis B virus (HBV) infection, with the majority of adult residents exposed to HBV during their childhood and 15-20% became HBV carrier. Reactivation of HBV, sometimes fulminant hepatic failure occurred, used to be one major issue after hematopoietic stem cell transplant (HSCT), now can be efficiently prevented by antiviral drug. However, reactivation of HBV by reverse seroconversion (HBV-RS) was sporadically reported in the patients who were socalled "cured or resolved HBV infection" (rHBV, HBsAgnegative, anti-HBc-positive) after immunotherapy, biological therapy, and after allo-HSCT. In this retrospective cohort study, we aim to report on the incidence, risk factors, and outcome of HBV-RS. Patients and Methods: Between January 2005 and September 2016, 914 consecutive patients receiving allo-HSCT at National Taiwan University Hospital were included. Every patient and their donors had complete HBV serology checkup, including HBsAg, anti-HBs, and anti-HBc. Of them, 448 (49%) patients were identified as rHBV. Their transplant data were collected following the EBMT Registry data collection forms and manuals. HBV-RS was defined as the detection of positive HBsAg and or detectable HBV DNA after Allo-HSCT. Donor with HBsAg positive was excluded. Liver biopsy was performed whenever clinically necessary to confirm the etiology. Univariate and multivariate analysis were performed using Cox proportional hazard regression model. This study was approved by the hospital Research Ethics Committee. Results There were 25 events (5.6%) of HBV-RS in 448 patients with rHBV after allo-HSCT. The cumulative incidence of HBV reactivation after allo-HSCT were 9% (95% CI: 0.06-0.13) at 3 years and 12.6% (95% CI: 0.08-0.18) at 5 years. The median time of HBV-RS was 1.2 years (ranges 0.02-11.3). Among them, 22 cases who had their HBV DNA PCR data examined all have concurrent HBV DNA activation (range 26 to 41 × 10 7 copies/ mL). Six patients developed HBV flare (ALT levels 45 times the upper limit), and none had fulminant hepatitis or died of hepatic failure. The risk factors for HBV-RS were: age over 50, reduced intensity conditioning, presence of chronic graftversus host disease (cGVHD), and donors negative for anti-HBs in the univariate analyses. In multivariate analysis, cGVHD was significantly associated with higher risk of HBV RS (HR: 10.656, 95% CI: 1.4-78.9, P = 0.0205). Interestingly, donors with antiHBs significantly reduced the recipient risk of HBV RS (HR: 0.359, 95% CI: 0.16-0.81, P = 0.0138), suggesting an adoptive donor immunity protection. Those patient developed episodes of HBV RS had a better 5-year OS than those without (63.6% vs 44.79%, P = 0.0118). The underlying mechanisms remained to be defined. Conclusion: Adoptive immunity transfer from donor seemingly renders protective effect against HBV RS after allo-HSCT for patients with rHBV, which may influence future donor selection algorithm. cGVHD also has a higher risk of HBV RS. On the other hand, in a tertiary medical center with close monitor and prompt intervention, the adverse impact of HBV RS complication could possibly be reversed. 
